{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"Response will be evaluated in this study using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1). Per RECIST v1.1 for target lesions: Complete Response (CR), Disappearance of all target lesions.\n\nPartial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions. Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease; For non-target lesions, CR: Disappearance of all non-target lesions. Stable Disease (SD), Persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. Clinical Benefit = CR + PR + SD. Defined as the number of patients with complete, partial response, or stable disease.","groups":[{"description":"Patients received oral cabozantinib 40 mg (as a starting dose) once per day and temozolomide 150 mg/m² on days 1-5 of a 28-day cycle for cycle one. Starting from cycle two, temozolomide was escalated to 200 mg/m² on days 1-5 of each cycle, if the absolute neutrophil count was more than 1·5 × 10⁹/L and platelet count was more than 100·0 × 10⁹/L. Treatment was continued until disease progression or unacceptable drug-related toxicity.","id":"OG000","title":"Cohort 1 - Patients With Unresectable or Metastatic Uterine and Non-uterine Leiomyosarcoma"},{"description":"Patients with gastrointestinal stromal tumour, dermatofibrosarcoma, alveolar soft part sarcoma, kaposi sarcoma, mixed mesodermal tumour or carcinosarcoma, alveolar and embryonal rhabdomyosarcoma, and low grade sarcomas were not included.\n\nPatients received oral cabozantinib 40 mg (as a starting dose) once per day and temozolomide 150 mg/m² on days 1-5 of a 28-day cycle for cycle one. Starting from cycle two, temozolomide was escalated to 200 mg/m² on days 1-5 of each cycle, if the absolute neutrophil count was more than 1·5 × 10⁹/L and platelet count was more than 100·0 × 10⁹/L. Treatment was continued until disease progression or unacceptable drug-related toxicity.","id":"OG001","title":"Cohort 2 - Patients With Other Soft Tissue Sarcomas"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At weeks 6 and 12, then every 2 cycles up to 5 years","title":"Clinical Benefit Rate","type":"SECONDARY","unitOfMeasure":"Participants"}